** Shares of ADMA Biologics ADMA.O hit a record high on Mon after the biopharmaceutical company won FDA approval for its plasma yield enhancement production process
** ADMA rose to as high as $25.67, highest level on record, and on track for the highest daily pct gain since Nov last year
** ADMA's process demonstrated an ability to increase production yields by approximately 20% from the same starting plasma volume
** "This approval represents a pivotal milestone for ADMA, unlocking the opportunity for meaningful acceleration in our revenue and earnings trajectory beginning in late 2025 and accelerating further into 2026 and beyond," said ADMA CEO Adam Grossman in a statement
** Among the 4 analysts that cover ADMA, the breakdown of recommendations are 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell"
** ADMA is up 45% YTD versus 0.53% gain in the S&P 500 health index .SPXHC
(Reporting by Chibuike Oguh in New York)
((Chibuike.Oguh@thomsonreuters.com; +332-219-1834; Reuters Messaging: chibuike.oguh.thomsonreuters.com@reuters.net))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.